Clinical trials: Vision Loss
Dim Light Vision Disturbances
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
The objectives of this study are: To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) To evaluate efficacy of Nyxol to improve visual…
- Trial name
- NCT04638660
- Testing
- Phentolamine Ophthalmic Solution 0.75%
- Where
- 17 sites in United States
- Volunteers
- 144 people
- Sponsor
- Opus Genetics, Inc
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor…
- Conditions
- Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
- Trial name
- CLARICO (NCT06789445)
- Testing
- OpCT-001
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- BlueRock Therapeutics
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Optic, Atrophy, Hereditary, Leber
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
The goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation…
- Trial name
- RESCUE (NCT02652767)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- GenSight Biologics
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Usher's Syndrome
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
- Trial name
- NCT02065011
- Testing
- Blood draw for the laboratory assessment
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Branch Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with…
- Trial name
- BRIGHTER (NCT01599650)
- Testing
- Ranibizumab, Laser
- Where
- 82 sites in Australia, Canada and 15 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
This was a Phase III, randomized, double-masked, multi-center, active-controlled, two-arm study designed to evaluate the efficacy and safety of brolucizumab 6 mg compared to the active control, aflibercept 2 mg used per…
- Trial name
- KITE (NCT03481660)
- Testing
- Brolucizumab, Aflibercept
- Where
- 78 sites in Belgium, Bulgaria and 21 more
- Volunteers
- 360 people
- Sponsor
- Novartis Pharmaceuticals
Visual Impairment
Measuring of Neuro-visual Functionality With Ocusweep
The aim of this study is to measure visual acuity, contrast sensitivity and visual field by SAP-method using a novel device Ocusweep compared to currently widely used methods.
- Trial name
- NCT02258113
- Testing
- Ocusweep, Ocusweep OcuRT
- Where
- Finland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Ocuspecto Oy
Retinitis Pigmentosa, Usher Syndrome Type 2
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
PQ-421a-002 (Helia) is an open-label, extension study to evaluate the safety, tolerability and efficacy of QR 421a (ultevursen) administered via intravitreal (IVT) injection in one or both eyes, in subjects ≥ 12 years of age with…
- Trial name
- HELIA (NCT05085964)
- Testing
- RNA antisense oligonucleotide for intravitreal injection
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Laboratoires Thea
Presbyopia
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.
- Trial name
- NCT05124275
- Testing
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3
- Where
- 10 sites in United States
- Volunteers
- 123 people
- Sponsor
- Glaukos Corporation
Weight Loss
Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist
The purpose of this pilot study is to demonstrate the anatomical modulation of subcutaneous fat across the waist and hips that occurs through application of the Erchonia® ML Scanner (MLS) Laser manufactured for non-invasive body…
- Trial name
- NCT01292564
- Testing
- Erchonia MLS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
AMD, Age-Related Macular Degeneration
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision…
- Trial name
- NCT04796545
- Testing
- SING IMT(TM) System, model NG SI IMT 3X
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- VisionCare, Inc.
Myopia, Pathological
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial.
- Trial name
- Myrror (NCT01249664)
- Testing
- VEGF Trap-Eye (BAY86-5321), No Drug
- Where
- 20 sites in Hong Kong, Japan and 3 more
- Volunteers
- 122 people
- Sponsor
- Bayer
Wolfram Syndrome
AMX0035 in Adult Patients With Wolfram Syndrome
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
- Trial name
- NCT05676034
- Testing
- AMX0035
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Retinitis Pigmentosa
Development of Visual Function Evaluation Method (2)
The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient.
- Trial name
- NCT03626207
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Astellas Pharma Inc
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion
- Trial name
- COMRADE-B (NCT01396057)
- Testing
- Ranibizumab, Dexamethasone Implant
- Where
- 66 sites in Czechia, Germany and 3 more
- Volunteers
- 244 people
- Sponsor
- Novartis Pharmaceuticals